摘要
目的观察麝香保心丸联合曲美他嗪治疗对慢性心力衰竭患者心功能的影响。方法 130例慢性心力衰竭患者分为2组。常规治疗组(A组,n=65):常规心力衰竭治疗方案;麝香保心丸组(B组,n=65):常规心力衰竭治疗方案的基础上,加用麝香保心丸,2粒,每日3次,曲美他嗪片,20 mg,每日3次。检查评估治疗前及治疗6个月后心功能分级、6 min步行试验、心脏超声心动图参数、超敏C反应蛋白(hs-CRP)水平。结果治疗6个月后,B组的心功能分级、6 min步行距离显著优于A组(P<0.05);B组治疗后左室舒张末期内径(left ventricular end-diastolic dimension,LVEDD),左室收缩末期内径(left ventricular end-systolic dimension,LVESD),hs-CRP均较A组显著减小(P<0.05);LVEF较A组显著增大(P<0.05)。结论常规心力衰竭治疗的基础上,加用麝香保心丸联合曲美他嗪治疗有效地改善慢性心力衰竭患者心功能。
Objective To study the effect of Shexiang Baoxin pill combined with trimetazidine Qumei on cardiac function in patients with chronic heart failure.Methods A total of 130 patients with chronic heart failure were randomly divided into： routine treatment group （group A, n = 65） ： conventional heart failure therapy; Shexiang Baoxin pill group （ group B, n = 65 ） ： conventional heart failure therapy combined with Shexiang Baoxin pill 2, 3 times a day, Qumei trimetazidine 20 mg, 3 times a day. Heart function classification, 6 min walk test, cardiac ultrasound heartbeat graph parameters, high sensitivity C-reactive protein （hs-CRP） level were assessed before treatment and 6 months later. Results After 6 months, heart function classification, 6 rain walking distance in group B were higher than that in group A （P〈0.05） ; left ventricular end-diastolic dimension （LVEDD） CRP in group B were significantly lower than group A （P 〈0.05 Additional use of Shexiang Baoxin pill and trimetazidine Qumei is chronic heart failure. left ventricular end-systolic dimension （LVESD） , hs-CRP in group B were significantly lower than group A （P 〈0.05 ）, LVEF on the contrary （P 〈 0.05 ）. Conclusion Additional use of Shexiang Baoxin pill and trimetazidine Qumei is effective in improving cardiac function in patients with chronic heart failure.
出处
《今日药学》
CAS
2014年第7期524-526,共3页
Pharmacy Today
关键词
麝香保心丸
曲美他嗪
慢性心力衰竭
Shexiang Baoxin pill
Qumei trimetazidine
chronic heart failure
